The Global Adherence Project (GAP): a multicenter observational study on adherence to disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosis
Identifieur interne : 006315 ( Main/Exploration ); précédent : 006314; suivant : 006316The Global Adherence Project (GAP): a multicenter observational study on adherence to disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosis
Auteurs : V. Devonshire ; Y. Lapierre [Canada] ; R. Macdonell [Australie] ; C. Ramo-Tello [Espagne] ; F. Patti [Italie] ; P. Fontoura [Portugal] ; L. Suchet [France] ; R. Hyde [Suisse] ; I. Balla [Suisse] ; E. M. Frohman [États-Unis] ; B. C. Kieseier [Allemagne]Source :
- European Journal of Neurology [ 1351-5101 ] ; 2011-01.
Descripteurs français
- Wicri :
- topic : Neurologie.
English descriptors
- KwdEn :
- Adherence, Adherence rate, Adherence rates, Adherent, Adherent patients, Adverse events, Advisory boards, Better quality, Biogen, Biogen idec, Cognitive dysfunction, Common problems, Common reason, Common symptom, Consulting fees, Czech republic, Disease activity, Disease duration, Disease history, Disease steps, Diseasemodifying therapy, Dmts, Dosing schedules, Efns, Efns european journal, European journal, Factors adherence, Glatiramer, Glatiramer acetate, Glatiramer acetate therapy, Global adherence project, Healthcare practitioners, Idec, Impairment, Important challenge, Injection, Injection anxiety, Injection site, Interferon, Interferon beta, Intramuscular interferon, Median, Median disease duration, Median months, Median time, Median years, Mild disability, Moderate disability, Msnq, Msnq data, Mult, Mult scler, Multiple sclerosis, Multivariate analysis, Musiqol, Neurologist, Neurology, Neuropsychological, Neuropsychological impairment, Neuropsychological screening questionnaire, Neurosci nurs, Nonadherent patients, Other dmts, Other reasons, Patient questionnaire, Patient questionnaires, Pharm assoc, Scler, Sclerosis, Shorter duration, Shorter period, Single dose, Skin reaction, Study group, Teva neuroscience, Therapeutic expectations, Therapy, Treatment adherence, Treatment duration, Treatment protocols, Treatment regimens, World health organization.
- Teeft :
- Adherence, Adherence rate, Adherence rates, Adherent, Adherent patients, Adverse events, Advisory boards, Better quality, Biogen, Biogen idec, Cognitive dysfunction, Common problems, Common reason, Common symptom, Consulting fees, Czech republic, Disease activity, Disease duration, Disease history, Disease steps, Diseasemodifying therapy, Dmts, Dosing schedules, Efns, Efns european journal, European journal, Factors adherence, Glatiramer, Glatiramer acetate, Glatiramer acetate therapy, Global adherence project, Healthcare practitioners, Idec, Impairment, Important challenge, Injection, Injection anxiety, Injection site, Interferon, Interferon beta, Intramuscular interferon, Median, Median disease duration, Median months, Median time, Median years, Mild disability, Moderate disability, Msnq, Msnq data, Mult, Mult scler, Multiple sclerosis, Multivariate analysis, Musiqol, Neurologist, Neurology, Neuropsychological, Neuropsychological impairment, Neuropsychological screening questionnaire, Neurosci nurs, Nonadherent patients, Other dmts, Other reasons, Patient questionnaire, Patient questionnaires, Pharm assoc, Scler, Sclerosis, Shorter duration, Shorter period, Single dose, Skin reaction, Study group, Teva neuroscience, Therapeutic expectations, Therapy, Treatment adherence, Treatment duration, Treatment protocols, Treatment regimens, World health organization.
Abstract
Background: Most disease‐modifying therapies (DMTs) for multiple sclerosis (MS) are self‐injectable medications that must be taken on an ongoing basis to reduce disease activity. Thus, adherence to therapy becomes an important challenge that must be addressed to maximize benefits of therapy. This study evaluated rates of adherence to prescribed treatment and explored factors affecting adherence amongst patients with relapsing‐remitting MS.
Url:
DOI: 10.1111/j.1468-1331.2010.03110.x
Affiliations:
- Allemagne, Australie, Canada, Espagne, France, Italie, Portugal, Suisse, États-Unis
- District de Düsseldorf, Provence-Alpes-Côte d'Azur, Rhénanie-du-Nord-Westphalie, Texas
- Düsseldorf, Marseille
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000553
- to stream Istex, to step Curation: 000553
- to stream Istex, to step Checkpoint: 000734
- to stream Main, to step Merge: 006691
- to stream Main, to step Curation: 006315
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Global Adherence Project (GAP): a multicenter observational study on adherence to disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosis</title><author><name sortKey="Devonshire, V" sort="Devonshire, V" uniqKey="Devonshire V" first="V." last="Devonshire">V. Devonshire</name></author><author><name sortKey="Lapierre, Y" sort="Lapierre, Y" uniqKey="Lapierre Y" first="Y." last="Lapierre">Y. Lapierre</name></author><author><name sortKey="Macdonell, R" sort="Macdonell, R" uniqKey="Macdonell R" first="R." last="Macdonell">R. Macdonell</name></author><author><name sortKey="Ramo Ello, C" sort="Ramo Ello, C" uniqKey="Ramo Ello C" first="C." last="Ramo-Tello">C. Ramo-Tello</name></author><author><name sortKey="Patti, F" sort="Patti, F" uniqKey="Patti F" first="F." last="Patti">F. Patti</name></author><author><name sortKey="Fontoura, P" sort="Fontoura, P" uniqKey="Fontoura P" first="P." last="Fontoura">P. Fontoura</name></author><author><name sortKey="Suchet, L" sort="Suchet, L" uniqKey="Suchet L" first="L." last="Suchet">L. Suchet</name></author><author><name sortKey="Hyde, R" sort="Hyde, R" uniqKey="Hyde R" first="R." last="Hyde">R. Hyde</name></author><author><name sortKey="Balla, I" sort="Balla, I" uniqKey="Balla I" first="I." last="Balla">I. Balla</name></author><author><name sortKey="Frohman, E M" sort="Frohman, E M" uniqKey="Frohman E" first="E. M." last="Frohman">E. M. Frohman</name></author><author><name sortKey="Kieseier, B C" sort="Kieseier, B C" uniqKey="Kieseier B" first="B. C." last="Kieseier">B. C. Kieseier</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1D9D729D840CC260FF4D765141F05E8E9E294D31</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1111/j.1468-1331.2010.03110.x</idno><idno type="url">https://api.istex.fr/document/1D9D729D840CC260FF4D765141F05E8E9E294D31/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000553</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000553</idno><idno type="wicri:Area/Istex/Curation">000553</idno><idno type="wicri:Area/Istex/Checkpoint">000734</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000734</idno><idno type="wicri:doubleKey">1351-5101:2011:Devonshire V:the:global:adherence</idno><idno type="wicri:Area/Main/Merge">006691</idno><idno type="wicri:Area/Main/Curation">006315</idno><idno type="wicri:Area/Main/Exploration">006315</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">The Global Adherence Project (GAP): a multicenter observational study on adherence to disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosis</title><author><name sortKey="Devonshire, V" sort="Devonshire, V" uniqKey="Devonshire V" first="V." last="Devonshire">V. Devonshire</name><affiliation><wicri:noCountry code="subField">BC</wicri:noCountry></affiliation></author><author><name sortKey="Lapierre, Y" sort="Lapierre, Y" uniqKey="Lapierre Y" first="Y." last="Lapierre">Y. Lapierre</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Hopital Neurologique de Montreal, Montreal, QC</wicri:regionArea><wicri:noRegion>QC</wicri:noRegion></affiliation></author><author><name sortKey="Macdonell, R" sort="Macdonell, R" uniqKey="Macdonell R" first="R." last="Macdonell">R. Macdonell</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Austin Hospital, Heidelberg, Vic.</wicri:regionArea><wicri:noRegion>Vic.</wicri:noRegion></affiliation></author><author><name sortKey="Ramo Ello, C" sort="Ramo Ello, C" uniqKey="Ramo Ello C" first="C." last="Ramo-Tello">C. Ramo-Tello</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario Germans Trias i Pujol Servicio De Neurologia, Badalona (Barcelona)</wicri:regionArea><wicri:noRegion>Badalona (Barcelona)</wicri:noRegion></affiliation></author><author><name sortKey="Patti, F" sort="Patti, F" uniqKey="Patti F" first="F." last="Patti">F. Patti</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>University of Catania, Catania</wicri:regionArea><wicri:noRegion>Catania</wicri:noRegion></affiliation></author><author><name sortKey="Fontoura, P" sort="Fontoura, P" uniqKey="Fontoura P" first="P." last="Fontoura">P. Fontoura</name><affiliation wicri:level="1"><country xml:lang="fr">Portugal</country><wicri:regionArea>New University of Lisbon, Lisbon</wicri:regionArea><wicri:noRegion>Lisbon</wicri:noRegion></affiliation></author><author><name sortKey="Suchet, L" sort="Suchet, L" uniqKey="Suchet L" first="L." last="Suchet">L. Suchet</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Cabinet Medical, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Hyde, R" sort="Hyde, R" uniqKey="Hyde R" first="R." last="Hyde">R. Hyde</name><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Biogen Idec International GmbH, Zug</wicri:regionArea><wicri:noRegion>Zug</wicri:noRegion></affiliation></author><author><name sortKey="Balla, I" sort="Balla, I" uniqKey="Balla I" first="I." last="Balla">I. Balla</name><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Biogen Idec International GmbH, Zug</wicri:regionArea><wicri:noRegion>Zug</wicri:noRegion></affiliation></author><author><name sortKey="Frohman, E M" sort="Frohman, E M" uniqKey="Frohman E" first="E. M." last="Frohman">E. M. Frohman</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Texas Southwestern Medical Center, Dallas, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Kieseier, B C" sort="Kieseier, B C" uniqKey="Kieseier B" first="B. C." last="Kieseier">B. C. Kieseier</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Heinrich‐Heine University, Düsseldorf</wicri:regionArea><placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region><region type="district" nuts="2">District de Düsseldorf</region><settlement type="city">Düsseldorf</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">European Journal of Neurology</title><title level="j" type="alt">EUROPEAN JOURNAL OF NEUROLOGY</title><idno type="ISSN">1351-5101</idno><idno type="eISSN">1468-1331</idno><imprint><biblScope unit="vol">18</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="69">69</biblScope><biblScope unit="page" to="77">77</biblScope><biblScope unit="page-count">9</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2011-01">2011-01</date></imprint><idno type="ISSN">1351-5101</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1351-5101</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adherence</term><term>Adherence rate</term><term>Adherence rates</term><term>Adherent</term><term>Adherent patients</term><term>Adverse events</term><term>Advisory boards</term><term>Better quality</term><term>Biogen</term><term>Biogen idec</term><term>Cognitive dysfunction</term><term>Common problems</term><term>Common reason</term><term>Common symptom</term><term>Consulting fees</term><term>Czech republic</term><term>Disease activity</term><term>Disease duration</term><term>Disease history</term><term>Disease steps</term><term>Diseasemodifying therapy</term><term>Dmts</term><term>Dosing schedules</term><term>Efns</term><term>Efns european journal</term><term>European journal</term><term>Factors adherence</term><term>Glatiramer</term><term>Glatiramer acetate</term><term>Glatiramer acetate therapy</term><term>Global adherence project</term><term>Healthcare practitioners</term><term>Idec</term><term>Impairment</term><term>Important challenge</term><term>Injection</term><term>Injection anxiety</term><term>Injection site</term><term>Interferon</term><term>Interferon beta</term><term>Intramuscular interferon</term><term>Median</term><term>Median disease duration</term><term>Median months</term><term>Median time</term><term>Median years</term><term>Mild disability</term><term>Moderate disability</term><term>Msnq</term><term>Msnq data</term><term>Mult</term><term>Mult scler</term><term>Multiple sclerosis</term><term>Multivariate analysis</term><term>Musiqol</term><term>Neurologist</term><term>Neurology</term><term>Neuropsychological</term><term>Neuropsychological impairment</term><term>Neuropsychological screening questionnaire</term><term>Neurosci nurs</term><term>Nonadherent patients</term><term>Other dmts</term><term>Other reasons</term><term>Patient questionnaire</term><term>Patient questionnaires</term><term>Pharm assoc</term><term>Scler</term><term>Sclerosis</term><term>Shorter duration</term><term>Shorter period</term><term>Single dose</term><term>Skin reaction</term><term>Study group</term><term>Teva neuroscience</term><term>Therapeutic expectations</term><term>Therapy</term><term>Treatment adherence</term><term>Treatment duration</term><term>Treatment protocols</term><term>Treatment regimens</term><term>World health organization</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Adherence</term><term>Adherence rate</term><term>Adherence rates</term><term>Adherent</term><term>Adherent patients</term><term>Adverse events</term><term>Advisory boards</term><term>Better quality</term><term>Biogen</term><term>Biogen idec</term><term>Cognitive dysfunction</term><term>Common problems</term><term>Common reason</term><term>Common symptom</term><term>Consulting fees</term><term>Czech republic</term><term>Disease activity</term><term>Disease duration</term><term>Disease history</term><term>Disease steps</term><term>Diseasemodifying therapy</term><term>Dmts</term><term>Dosing schedules</term><term>Efns</term><term>Efns european journal</term><term>European journal</term><term>Factors adherence</term><term>Glatiramer</term><term>Glatiramer acetate</term><term>Glatiramer acetate therapy</term><term>Global adherence project</term><term>Healthcare practitioners</term><term>Idec</term><term>Impairment</term><term>Important challenge</term><term>Injection</term><term>Injection anxiety</term><term>Injection site</term><term>Interferon</term><term>Interferon beta</term><term>Intramuscular interferon</term><term>Median</term><term>Median disease duration</term><term>Median months</term><term>Median time</term><term>Median years</term><term>Mild disability</term><term>Moderate disability</term><term>Msnq</term><term>Msnq data</term><term>Mult</term><term>Mult scler</term><term>Multiple sclerosis</term><term>Multivariate analysis</term><term>Musiqol</term><term>Neurologist</term><term>Neurology</term><term>Neuropsychological</term><term>Neuropsychological impairment</term><term>Neuropsychological screening questionnaire</term><term>Neurosci nurs</term><term>Nonadherent patients</term><term>Other dmts</term><term>Other reasons</term><term>Patient questionnaire</term><term>Patient questionnaires</term><term>Pharm assoc</term><term>Scler</term><term>Sclerosis</term><term>Shorter duration</term><term>Shorter period</term><term>Single dose</term><term>Skin reaction</term><term>Study group</term><term>Teva neuroscience</term><term>Therapeutic expectations</term><term>Therapy</term><term>Treatment adherence</term><term>Treatment duration</term><term>Treatment protocols</term><term>Treatment regimens</term><term>World health organization</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Neurologie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract">Background: Most disease‐modifying therapies (DMTs) for multiple sclerosis (MS) are self‐injectable medications that must be taken on an ongoing basis to reduce disease activity. Thus, adherence to therapy becomes an important challenge that must be addressed to maximize benefits of therapy. This study evaluated rates of adherence to prescribed treatment and explored factors affecting adherence amongst patients with relapsing‐remitting MS.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Canada</li><li>Espagne</li><li>France</li><li>Italie</li><li>Portugal</li><li>Suisse</li><li>États-Unis</li></country><region><li>District de Düsseldorf</li><li>Provence-Alpes-Côte d'Azur</li><li>Rhénanie-du-Nord-Westphalie</li><li>Texas</li></region><settlement><li>Düsseldorf</li><li>Marseille</li></settlement></list><tree><noCountry><name sortKey="Devonshire, V" sort="Devonshire, V" uniqKey="Devonshire V" first="V." last="Devonshire">V. Devonshire</name></noCountry><country name="Canada"><noRegion><name sortKey="Lapierre, Y" sort="Lapierre, Y" uniqKey="Lapierre Y" first="Y." last="Lapierre">Y. Lapierre</name></noRegion></country><country name="Australie"><noRegion><name sortKey="Macdonell, R" sort="Macdonell, R" uniqKey="Macdonell R" first="R." last="Macdonell">R. Macdonell</name></noRegion></country><country name="Espagne"><noRegion><name sortKey="Ramo Ello, C" sort="Ramo Ello, C" uniqKey="Ramo Ello C" first="C." last="Ramo-Tello">C. Ramo-Tello</name></noRegion></country><country name="Italie"><noRegion><name sortKey="Patti, F" sort="Patti, F" uniqKey="Patti F" first="F." last="Patti">F. Patti</name></noRegion></country><country name="Portugal"><noRegion><name sortKey="Fontoura, P" sort="Fontoura, P" uniqKey="Fontoura P" first="P." last="Fontoura">P. Fontoura</name></noRegion></country><country name="France"><region name="Provence-Alpes-Côte d'Azur"><name sortKey="Suchet, L" sort="Suchet, L" uniqKey="Suchet L" first="L." last="Suchet">L. Suchet</name></region></country><country name="Suisse"><noRegion><name sortKey="Hyde, R" sort="Hyde, R" uniqKey="Hyde R" first="R." last="Hyde">R. Hyde</name></noRegion><name sortKey="Balla, I" sort="Balla, I" uniqKey="Balla I" first="I." last="Balla">I. Balla</name></country><country name="États-Unis"><region name="Texas"><name sortKey="Frohman, E M" sort="Frohman, E M" uniqKey="Frohman E" first="E. M." last="Frohman">E. M. Frohman</name></region></country><country name="Allemagne"><region name="Rhénanie-du-Nord-Westphalie"><name sortKey="Kieseier, B C" sort="Kieseier, B C" uniqKey="Kieseier B" first="B. C." last="Kieseier">B. C. Kieseier</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006315 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006315 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:1D9D729D840CC260FF4D765141F05E8E9E294D31
|texte= The Global Adherence Project (GAP): a multicenter observational study on adherence to disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosis
}}
| This area was generated with Dilib version V0.6.33. |  |